Author: "Sanchez-Menoyo, Jose Luis" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Sanchez-Menoyo, Jose Luis"' showing total 89 results

Start Over Author "Sanchez-Menoyo, Jose Luis"

89 results on '"Sanchez-Menoyo, Jose Luis"'

1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Author: Lal, Anoushka P., Foong, Yi Chao, Sanfilippo, Paul G., Spelman, Tim, Rath, Louise, Levitz, David, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas-Robledo, Simón, Moghadasi, Abdorreza Naser, Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, and Van der Walt, Anneke
Published: 2024
Full Text: View/download PDF

2. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis

Author: Sabin, Julia, Salas, Elisa, Martín-Martínez, Jesús, Candeliere-Merlicco, Antonio, Barrero, Francisco Javier, Alonso, Ana, Sánchez-Menoyo, José Luis, Borrega, Laura, Rodríguez-Rodríguez, María, Gómez-Gutiérrez, Montserrat, Eichau, Sara, Hernández-Pérez, Miguel Ángel, Calles, Carmen, Fernández-Díaz, Eva, Carmona, Olga, Orviz, Aida, López-Real, Ana, López-Muñoz, Pablo, Mendonza, Amelia, Agüera, Eduardo, and Maurino, Jorge
Published: 2024
Full Text: View/download PDF

3. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author: Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, Vukusic, Sandra, Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, and Kalincik, Tomas
Published: 2024
Full Text: View/download PDF

4. Longitudinal modeling of MS patient trajectories improves predictions of disability progression

Author: De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, GrandMaison, Francois, Bergamaschi, Roberto, Sa, Maria Jose, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannej, Vahid, Moore, Fraser, Guevara, Celia Oreja, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, and Peeters, Liesbet
Subjects: Computer Science - Machine Learning
Abstract: Research in Multiple Sclerosis (MS) has recently focused on extracting knowledge from real-world clinical data sources. This type of data is more abundant than data produced during clinical trials and potentially more informative about real-world clinical practice. However, this comes at the cost of less curated and controlled data sets. In this work, we address the task of optimally extracting information from longitudinal patient data in the real-world setting with a special focus on the sporadic sampling problem. Using the MSBase registry, we show that with machine learning methods suited for patient trajectories modeling, such as recurrent neural networks and tensor factorization, we can predict disability progression of patients in a two-year horizon with an ROC-AUC of 0.86, which represents a 33% decrease in the ranking pair error (1-AUC) compared to reference methods using static clinical features. Compared to the models available in the literature, this work uses the most complete patient history for MS disease progression prediction.
Published: 2020

5. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

Author: De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, José Sá, Maria, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannejad, Vahid, Moore, Fraser, Oreja-Guevara, Celia, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, and Peeters, Liesbet
Published: 2021
Full Text: View/download PDF

6. Acute Viral Encephalitis: Herpesviruses and Enteroviruses

Author: Sánchez-Menoyo, José Luis, Portillo, Jone Bocos, and García-Moncó, Juan Carlos, editor
Published: 2018
Full Text: View/download PDF

7. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

Author: Fragoso, Yara Dadalti, Spelman, Tim, Boz, Cavit, Alroughani, Raed, Lugaresi, Alessandra, Vucic, Steve, Butzkueven, Helmut, Terzi, Murat, Havrdova, Eva, Horakova, Dana, Granella, Franco, Olascoaga, Javier, Sánchez-Menoyo, José Luis, Pucci, Eugenio, Barnett, Michael, Brooks, Joseph Bruno B., and Haartsen, Jodi
Published: 2018
Full Text: View/download PDF

8. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Author: Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, GrandʼMaison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, and Butzkueven, Helmut
Published: 2020
Full Text: View/download PDF

9. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author: Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, Kalincik, Tomas, Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, and Vukusic, Sandra
Abstract: High-efficacy disease-modifying therapies have been proven to slow disability accrual in adults with relapsing–remitting multiple sclerosis. However, their impact on disability worsening in paediatric-onset multiple sclerosis, particularly during the early phases, is not well understood. We evaluated how high-efficacy therapies influence transitions across five disability states, ranging from minimal disability to gait impairment and secondary progressive multiple sclerosis, in people with paediatric-onset multiple sclerosis.
Published: 2024
Full Text: View/download PDF

10. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

Author: Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Spelman, Tim; Ozakbas, Serkan; Alroughani, Raed; Terzi, Murat; Hodgkinson, Suzanne; Laureys, Guy; Kalincik, Tomas; Van der Walt, Anneke; Yamout, Bassem; Lechner-Scott, Jeannette; Soysal, Aysun; Kuhle, Jens; Sanchez-Menoyo, Jose Luis; Morgado, Yolanda Blanco; Spitaleri, Daniele L. A.; van Pesch, Vincent; Horakova, Dana; Ampapa, Radek; Patti, Francesco; Macdonell, Richard; Al-Asmi, Abdullah; Gerlach, Oliver; Oh, Jiwon; Tundia, Namita; Wong, Schiffon L.; Butzkueven, Helmut; MSBase Study Group, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Spelman, Tim; Ozakbas, Serkan; Alroughani, Raed; Terzi, Murat; Hodgkinson, Suzanne; Laureys, Guy; Kalincik, Tomas; Van der Walt, Anneke; Yamout, Bassem; Lechner-Scott, Jeannette; Soysal, Aysun; Kuhle, Jens; Sanchez-Menoyo, Jose Luis; Morgado, Yolanda Blanco; Spitaleri, Daniele L. A.; van Pesch, Vincent; Horakova, Dana; Ampapa, Radek; Patti, Francesco; Macdonell, Richard; Al-Asmi, Abdullah; Gerlach, Oliver; Oh, Jiwon; Tundia, Namita; Wong, Schiffon L.; Butzkueven, Helmut; MSBase Study Group, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
Abstract: What is this summary about? Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments. What were the results? Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. What do the results mean? The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS., Merck
Published: 2023

11. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Author: Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Diouf, Ibrahima; Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Horakova, Dana; Havrdova, Eva Kubala; Patti, Francesco; Shaygannejad, Vahid; Ozakbas, Serkan; Izquierdo, Guillermo; Eichau, Sara; Onofrj, Marco; Lugaresi, Alessandra; Alroughani, Raed; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Terzi, Murat; Boz, Cavit; Grand'Maison, Francois; Hamdy, Sherif; Sola, Patrizia; Ferraro, Diana; Grammond, Pierre; Turkoglu, Recai; Buzzard, Katherine; Skibina, Olga; Yamout, Bassem; Gerlach, Oliver; van Pesch, Vincent; Blanco, Yolanda; Maimone, Davide; Lechner-Scott, Jeannette; Bergamaschi, Roberto; Karabudak, Rana; Iuliano, Gerardo; McGuigan, Chris; Cartechini, Elisabetta; Barnett, Michael; Hughes, Stella; Sa, Maria Jose; Solaro, Claudio; Kappos, Ludwig; Ramo-Tello, Cristina; Cristiano, Edgardo; Hodgkinson, Suzanne; Spitaleri, Daniele; Soysal, Aysun; Petersen, Thor; Slee, Mark; Butler, Ernest; Granella, Franco; de Gans, Koen; McCombe, Pamela; Ampapa, Radek; Van Wijmeersch, Bart; van der Walt, Anneke; Butzkueven, Helmut; Prevost, Julie; Sinnige, L. G. F.; Sanchez-Menoyo, Jose Luis; Vucic, Steve; Laureys, Guy; Van Hijfte, Liesbeth; Khurana, Dheeraj; Macdonell, Richard; Gouider, Riadh; Castillo-Trivino, Tamara; Gray, Orla; Aguera-Morales, Eduardo; Al-Asmi, Abdullah; Shaw, Cameron; Deri, Norma; Al-Harbi, Talal; Fragoso, Yara; Csepany, Tunde; Sempere, Angel Perez; Trevino-Frenk, Irene; Schepel, Jan; Moore, Fraser; Kalincik, Tomas, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, Altıntaş, Ayşe (ORCID 0000-0002-8524-5087 & YÖK ID 11611), Diouf, Ibrahima; Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Horakova, Dana; Havrdova, Eva Kubala; Patti, Francesco; Shaygannejad, Vahid; Ozakbas, Serkan; Izquierdo, Guillermo; Eichau, Sara; Onofrj, Marco; Lugaresi, Alessandra; Alroughani, Raed; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Terzi, Murat; Boz, Cavit; Grand'Maison, Francois; Hamdy, Sherif; Sola, Patrizia; Ferraro, Diana; Grammond, Pierre; Turkoglu, Recai; Buzzard, Katherine; Skibina, Olga; Yamout, Bassem; Gerlach, Oliver; van Pesch, Vincent; Blanco, Yolanda; Maimone, Davide; Lechner-Scott, Jeannette; Bergamaschi, Roberto; Karabudak, Rana; Iuliano, Gerardo; McGuigan, Chris; Cartechini, Elisabetta; Barnett, Michael; Hughes, Stella; Sa, Maria Jose; Solaro, Claudio; Kappos, Ludwig; Ramo-Tello, Cristina; Cristiano, Edgardo; Hodgkinson, Suzanne; Spitaleri, Daniele; Soysal, Aysun; Petersen, Thor; Slee, Mark; Butler, Ernest; Granella, Franco; de Gans, Koen; McCombe, Pamela; Ampapa, Radek; Van Wijmeersch, Bart; van der Walt, Anneke; Butzkueven, Helmut; Prevost, Julie; Sinnige, L. G. F.; Sanchez-Menoyo, Jose Luis; Vucic, Steve; Laureys, Guy; Van Hijfte, Liesbeth; Khurana, Dheeraj; Macdonell, Richard; Gouider, Riadh; Castillo-Trivino, Tamara; Gray, Orla; Aguera-Morales, Eduardo; Al-Asmi, Abdullah; Shaw, Cameron; Deri, Norma; Al-Harbi, Talal; Fragoso, Yara; Csepany, Tunde; Sempere, Angel Perez; Trevino-Frenk, Irene; Schepel, Jan; Moore, Fraser; Kalincik, Tomas, Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), and School of Medicine
Abstract: Background and purpose: This study assessed the effect of patient characteristics on the response to disease-modifying therapy (DMT) in multiple sclerosis (MS). Methods: We extracted data from 61,810 patients from 135 centers across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS, follow-up ? 1 year, and Expanded Disability Status Scale (EDSS) score ? 3, with ?1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. Results: Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio [HR] = 0.52, 95% confidence interval [CI] = 0.45–0.60), 46% lower risk of disability worsening (HR = 0.54, 95% CI = 0.41–0.71), and 32% greater chance of disability improvement (HR = 1.32, 95% CI = 1.09–1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral magnetic resonance imaging activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. Conclusions: DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence of attenuation of the effect of DMT with age., This study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766, 1080518).
Published: 2023

12. Acute Viral Encephalitis: Herpesviruses and Enteroviruses

Author: Sánchez-Menoyo, José Luis, Ruiz-Ojeda, Javier, and García-Moncó, Juan Carlos, editor
Published: 2014
Full Text: View/download PDF

13. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author: Daruwalla, Cyrus, primary, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Havrdova, Eva Kubala, additional, Horakova, Dana, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Patti, Francesco, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Duquette, Pierre, additional, Yamout, Bassem, additional, Khoury, Samia J, additional, Sajedi, Seyed Aidin, additional, Turkoglu, Recai, additional, Altintas, Ayse, additional, Skibina, Olga, additional, Buzzard, Katherine, additional, Grammond, Pierre, additional, Karabudak, Rana, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Soysal, Aysun, additional, John, Nevin, additional, Prevost, Julie, additional, Spitaleri, Daniele, additional, Ramo-Tello, Cristina, additional, Gerlach, Oliver, additional, Iuliano, Gerardo, additional, Foschi, Matteo, additional, Ampapa, Radek, additional, van Pesch, Vincent, additional, Barnett, Michael, additional, Shalaby, Nevin, additional, D’hooghe, Marie, additional, Kuhle, Jens, additional, Sa, Maria Jose, additional, Fabis-Pedrini, Marzena, additional, Kermode, Allan, additional, Mrabet, Saloua, additional, Gouider, Riadh, additional, Hodgkinson, Suzanne, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Macdonell, Richard, additional, Oreja-Guevara, Celia, additional, Cristiano, Edgardo, additional, McCombe, Pamela, additional, Sanchez-Menoyo, Jose Luis, additional, Singhal, Bhim, additional, Blanco, Yolanda, additional, Hughes, Stella, additional, Garber, Justin, additional, Solaro, Claudio, additional, McGuigan, Chris, additional, Taylor, Bruce, additional, de Gans, Koen, additional, Habek, Mario, additional, Al-Asmi, Abdullah, additional, Mihaela, Simu, additional, Castillo Triviño, Tamara, additional, Al-Harbi, Talal, additional, Rojas, Juan Ignacio, additional, Gray, Orla, additional, Khurana, Dheeraj, additional, Van Wijmeersch, Bart, additional, Grigoriadis, Nikolaos, additional, Inshasi, Jihad, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Fragoso, Yara, additional, Moore, Fraser, additional, Shaw, Cameron, additional, Baghbanian, Seyed Mohammad, additional, Shuey, Neil, additional, Willekens, Barbara, additional, Hardy, Todd A, additional, Decoo, Danny, additional, sempere, Angel Perez, additional, Field, Deborah, additional, Wynford-Thomas, Ray, additional, Cunniffe, Nick G, additional, Roos, Izanne, additional, Malpas, Charles B, additional, Coles, Alasdair J, additional, Kalincik, Tomas, additional, and Brown, J William L, additional
Published: 2023
Full Text: View/download PDF

14. Comparative effectiveness in multiple sclerosis: A methodological comparison

Author: Roos, Izanne, primary, Diouf, Ibrahima, additional, Sharmin, Sifat, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamou, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Ramo-Tello, Cristina, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sanchez-Menoyo, Jose Luis, additional, Laureys, Guy, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Al-Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel Perez, additional, Trevino-Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, Malpas, Charles, additional, and Kalincik, Tomas, additional
Published: 2023
Full Text: View/download PDF

15. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

Author: Diouf, Ibrahima, primary, Malpas, Charles B., additional, Sharmin, Sifat, additional, Roos, Izanne, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand'Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Gerlach, Oliver, additional, van Pesch, Vincent, additional, Blanco, Yolanda, additional, Maimone, Davide, additional, Lechner‐Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Chris, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria José, additional, Solaro, Claudio, additional, Kappos, Ludwig, additional, Ramo‐Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, de Gans, Koen, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Van Wijmeersch, Bart, additional, van der Walt, Anneke, additional, Butzkueven, Helmut, additional, Prevost, Julie, additional, Sinnige, L. G. F., additional, Sanchez‐Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Gouider, Riadh, additional, Castillo‐Triviño, Tamara, additional, Gray, Orla, additional, Aguera‐Morales, Eduardo, additional, Al‐Asmi, Abdullah, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al‐Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Perez Sempere, Angel, additional, Trevino‐Frenk, Irene, additional, Schepel, Jan, additional, Moore, Fraser, additional, and Kalincik, Tomas, additional
Published: 2023
Full Text: View/download PDF

16. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis

Author: Kalincik, Tomas, Sharmin, Sifat, Roos, Izanne, Freedman, Mark S., Atkins, Harold, Burman, Joachim, Massey, Jennifer, Sutton, Ian, Withers, Barbara, Macdonell, Richard, Grigg, Andrew, Torkildsen, Øivind, Bo, Lars, Lehmann, Anne Kristine, Havrdova, Eva Kubala, Krasulova, Eva, Trněný, Marek, Kozak, Tomas, van der Walt, Anneke, Butzkueven, Helmut, McCombe, Pamela, Skibina, Olga, Lechner-Scott, Jeannette, Willekens, Barbara, Cartechini, Elisabetta, Ozakbas, Serkan, Alroughani, Raed, Kuhle, Jens, Patti, Francesco, Duquette, Pierre, Lugaresi, Alessandra, Khoury, Samia J., Slee, Mark, Turkoglu, Recai, Hodgkinson, Suzanne, John, Nevin, Maimone, Davide, Sa, Maria Jose, van Pesch, Vincent, Gerlach, Oliver, Laureys, Guy, Van Hijfte, Liesbeth, Karabudak, Rana, Spitaleri, Daniele, Csepany, Tunde, Gouider, Riadh, Castillo-Triviño, Tamara, Taylor, Bruce, Sharrack, Basil, Snowden, John A., Horakova, Dana, Buzzard, Katherine, Terzi, Murat, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Barnett, Michael, Stewart, Grace, Onofrj, Marco, Izquierdo, Guillermo, Eichau, Sara, Grand'Maison, Francois, Prevost, Julie, Van Wijmeersch, Bart, Amato, Maria Pia, Shaygannejad, Vahid, Boz, Cavit, Bolaños, Ricardo Fernandez, Soysal, Aysun, Ramo-Tello, Cristina, Solaro, Claudio, Gobbi, Claudio, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Deri, Norma, Saladino, Maria Laura, Cristiano, Edgardo, Rojas, Juan Ignacio, Vrech, Carlos, Shaw, Cameron, Shuey, Neil, Boggild, Mike, Tan, Ik Lin, Hardy, Todd, Decoo, Danny, Moore, Fraser, Oh, Jiwon, Lalive, Patrice, Ampapa, Radek, Petersen, Thor, Oreja-Guevara, Celia, Perez Sempere, Angel, Dominguez, Jose Andres, Besora, Sarah, Hughes, Stella, Gray, Orla, Grigoriadis, Nikolaos, Piroska, Imre, Rozsa, Csilla, Kasa, Krisztian, Simo, Magdolna, Kovacs, Krisztina, Sas, Attila, Dobos, Eniko, Rajda, Cecilia, McGuigan, Chris, Mason, Deborah, Schepel, Jan, Alkhaboori, Jabir, Rio, Maria Edite, Mihaela, Simu, Al-Harbi, Talal, Altintas, Ayse, Kister, Ilya, Marriott, Mark, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Diamanti, Matteo, Chisari, Clara, Toscano, Simona, Salvatore, Lo Fermo, Larochelle, Catherine, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hupperts, Raymond, Olascoaga, Javier, Saiz, Albert, Zivadinov, Robert, Benedict, Ralph, Verheul, Freek, Fabis-Pedrini, Marzena, Mrabet, Saloua, Garber, Justin, Sanchez-Menoyo, Jose Luis, Aguera-Morales, Eduardo, Blanco, Yolanda, Al-Asmi, Abdullah, Weinstock-Guttman, Bianca, Fragoso, Yara, de Gans, Koen, and Kermode, Allan
Subjects: Human medicine
Abstract: you are agreeing to our Cookie Policy | Continue JAMA Network HomeJAMA Neurology This Issue Views 2,357 Citations 0 60 Full Text Share Comment Original Investigation May 15, 2023 Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis Tomas Kalincik, MD, PhD1,2; Sifat Sharmin, PhD1,2; Izanne Roos, MBChB, PhD1,2; Mark S. Freedman, MD3; Harold Atkins, MD4; Joachim Burman, MD, PhD5; Jennifer Massey, MBBS, PhD6,7; Ian Sutton, MBBS, PhD6,8; Barbara Withers, MD, PhD7,9; Richard Macdonell, MD, PhD10,11; Andrew Grigg, MD, PhD11,12; Øivind Torkildsen, MD, PhD13; Lars Bo, MD, PhD13; Anne Kristine Lehmann, MD, PhD14; Eva Kubala Havrdova, MD, PhD15; Eva Krasulova, MD, PhD15; Marek Trněný, MD, PhD16; Tomas Kozak, MD, PhD17; Anneke van der Walt, MBBS, PhD18,19; Helmut Butzkueven, MBBS, PhD18,19; Pamela McCombe, MBBS20,21; Olga Skibina, MBBS18,22,23; Jeannette Lechner-Scott, MD, PhD24,25; Barbara Willekens, MD, PhD26,27; Elisabetta Cartechini, MD28; Serkan Ozakbas, MD29; Raed Alroughani, MD30; Jens Kuhle, MD, PhD31; Francesco Patti, MD32,33; Pierre Duquette, MD34; Alessandra Lugaresi, MD, PhD35,36; Samia J. Khoury, MD, PhD37; Mark Slee, MD, PhD38; Recai Turkoglu, MD39; Suzanne Hodgkinson, MD40; Nevin John, MD, PhD41,42; Davide Maimone, MD43; Maria Jose Sa, MD44; Vincent van Pesch, MD, PhD45,46; Oliver Gerlach, MD, PhD47,48; Guy Laureys, MD49; Liesbeth Van Hijfte, MD49; Rana Karabudak, MD50; Daniele Spitaleri, MD51; Tunde Csepany, MD, PhD52; Riadh Gouider, MD53,54; Tamara Castillo-Triviño, MD55; Bruce Taylor, MD, PhD56,57; Basil Sharrack, MD, PhD58; John A. Snowden, MD, PhD59; and the MSBase Study Group Collaborators; and the MSBase Study Group Authors Author Affiliations JAMA Neurol. 2023;80(7):702-713. doi:10.1001/jamaneurol.2023.1184 editorial comment iconEditorial Comment Key Points Question What is the comparative effectiveness of autologous hematopoietic stem cell transplant (AHSCT) vs individual most potent disease-modifying therapies for relapsing-remitting multiple sclerosis (MS), such as natalizumab or ocrelizumab? Findings In this observational comparative effectiveness study of 4915 individuals using a composite cohort from specialized MS centers and the MSBase international registry, the effectiveness of AHSCT was compared with 1 medium-efficacy and 2 high-efficacy disease-modifying therapies (fingolimod, natalizumab, and ocrelizumab) in patients with relapsing-remitting MS, high frequency of relapses, and moderate disability. Over 5 years, AHSCT was associated with substantially lower relapse rate than fingolimod and marginally lower relapse rate than natalizumab and was also associated with a higher rate of recovery from disability compared with fingolimod and natalizumab, but no evidence of difference in clinical outcomes between AHSCT and ocrelizumab was found at 3-year follow-up. Meaning The results indicate that in relapsing-remitting MS, the clinical effectiveness of AHSCT is considerably superior to fingolimod and marginally superior to natalizumab. Abstract Importance Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, Setting, and Participants This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.
Published: 2023

17. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

Author: Spelman, Tim, Ozakbas, Serkan, Alroughani, Raed, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele LA, Pesch, Vincent van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Al-Asmi, Abdullah, Gerlach, Oliver, Oh, Jiwon, Altintas, Ayse, Tundia, Namita, Wong, Schiffon L, Butzkueven, Helmut, MSBase Study Group, [missing], and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire
Subjects: teriflunomide (Aubagio®), relapses, cladribine tablets, fingolimod (Gilenya®), Neurology (clinical), lay summary, dimethyl fumarate (Tecfidera®), multiple sclerosis, treatment options
Abstract: What is this summary about? Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. What were the results? Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. What do the results mean? The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
Published: 2023

18. sj-docx-1-msj-10.1177_13524585231151951 – Supplemental material for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author: Daruwalla, Cyrus, Shaygannejad, Vahid, Ozakbas, Serkan, Havrdova, Eva Kubala, Horakova, Dana, Alroughani, Raed, Boz, Cavit, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J, Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Buzzard, Katherine, Grammond, Pierre, Karabudak, Rana, van der Walt, Anneke, Butzkueven, Helmut, Maimone, Davide, Lechner-Scott, Jeannette, Soysal, Aysun, John, Nevin, Prevost, Julie, Spitaleri, Daniele, Ramo-Tello, Cristina, Gerlach, Oliver, Iuliano, Gerardo, Foschi, Matteo, Ampapa, Radek, van Pesch, Vincent, Barnett, Michael, Shalaby, Nevin, D’hooghe, Marie, Kuhle, Jens, Sa, Maria Jose, Fabis-Pedrini, Marzena, Kermode, Allan, Mrabet, Saloua, Gouider, Riadh, Hodgkinson, Suzanne, Laureys, Guy, Van Hijfte, Liesbeth, Macdonell, Richard, Oreja-Guevara, Celia, Cristiano, Edgardo, McCombe, Pamela, Sanchez-Menoyo, Jose Luis, Singhal, Bhim, Blanco, Yolanda, Hughes, Stella, Garber, Justin, Solaro, Claudio, McGuigan, Chris, Taylor, Bruce, de Gans, Koen, Habek, Mario, Al-Asmi, Abdullah, Mihaela, Simu, Castillo Triviño, Tamara, Al-Harbi, Talal, Rojas, Juan Ignacio, Gray, Orla, Khurana, Dheeraj, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Inshasi, Jihad, Oh, Jiwon, Aguera-Morales, Eduardo, Fragoso, Yara, Moore, Fraser, Shaw, Cameron, Baghbanian, Seyed Mohammad, Shuey, Neil, Willekens, Barbara, Hardy, Todd A, Decoo, Danny, sempere, Angel Perez, Field, Deborah, Wynford-Thomas, Ray, Cunniffe, Nick G, Roos, Izanne, Malpas, Charles B, Coles, Alasdair J, Kalincik, Tomas, and Brown, J William L
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, sj-docx-1-msj-10.1177_13524585231151951 for Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis by Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Raed Alroughani, Cavit Boz, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Sara Eichau, Marc Girard, Alexandre Prat, Pierre Duquette, Bassem Yamout, Samia J Khoury, Seyed Aidin Sajedi, Recai Turkoglu, Ayse Altintas, Olga Skibina, Katherine Buzzard, Pierre Grammond, Rana Karabudak, Anneke van der Walt, Helmut Butzkueven, Davide Maimone, Jeannette Lechner-Scott, Aysun Soysal, Nevin John, Julie Prevost, Daniele Spitaleri, Cristina Ramo-Tello, Oliver Gerlach, Gerardo Iuliano, Matteo Foschi, Radek Ampapa, Vincent van Pesch, Michael Barnett, Nevin Shalaby, Marie D’hooghe, Jens Kuhle, Maria Jose Sa, Marzena Fabis-Pedrini, Allan Kermode, Saloua Mrabet, Riadh Gouider, Suzanne Hodgkinson, Guy Laureys, Liesbeth Van Hijfte, Richard Macdonell, Celia Oreja-Guevara, Edgardo Cristiano, Pamela McCombe, Jose Luis Sanchez-Menoyo, Bhim Singhal, Yolanda Blanco, Stella Hughes, Justin Garber, Claudio Solaro, Chris McGuigan, Bruce Taylor, Koen de Gans, Mario Habek, Abdullah Al-Asmi, Simu Mihaela, Tamara Castillo Triviño, Talal Al-Harbi, Juan Ignacio Rojas, Orla Gray, Dheeraj Khurana, Bart Van Wijmeersch, Nikolaos Grigoriadis, Jihad Inshasi, Jiwon Oh, Eduardo Aguera-Morales, Yara Fragoso, Fraser Moore, Cameron Shaw, Seyed Mohammad Baghbanian, Neil Shuey, Barbara Willekens, Todd A Hardy, Danny Decoo, Angel Perez sempere, Deborah Field, Ray Wynford-Thomas, Nick G Cunniffe, Izanne Roos, Charles B Malpas, Alasdair J Coles, Tomas Kalincik and J William L Brown in Multiple Sclerosis Journal
Published: 2023
Full Text: View/download PDF

19. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Author: Spelman, Tim, primary, Ozakbas, Serkan, additional, Alroughani, Raed, additional, Terzi, Murat, additional, Hodgkinson, Suzanne, additional, Laureys, Guy, additional, Kalincik, Tomas, additional, Van Der Walt, Anneke, additional, Yamout, Bassem, additional, Lechner-Scott, Jeannette, additional, Soysal, Aysun, additional, Kuhle, Jens, additional, Sanchez-Menoyo, Jose Luis, additional, Blanco Morgado, Yolanda, additional, Spitaleri, Daniele LA, additional, van Pesch, Vincent, additional, Horakova, Dana, additional, Ampapa, Radek, additional, Patti, Francesco, additional, Macdonell, Richard, additional, Al-Asmi, Abdullah, additional, Gerlach, Oliver, additional, Oh, Jiwon, additional, Altintas, Ayse, additional, Tundia, Namita, additional, Wong, Schiffon L, additional, and Butzkueven, Helmut, additional
Published: 2022
Full Text: View/download PDF

20. Machine-learning-based prediction of disability progression in multiple sclerosis: an observational, international, multi-center study

Author: De Brouwer, Edward, primary, Becker, Thijs, additional, Werthen-Brabants, Lorin, additional, Dewulf, Pieter, additional, Iliadis, Dimitrios, additional, Dekeyser, Cathérine, additional, Laureys, Guy, additional, Van Wijmeersch, Bart, additional, Popescu, Veronica, additional, Dhaene, Tom, additional, Deschrijver, Dirk, additional, Waegeman, Willem, additional, De Baets, Bernard, additional, Stock, Michiel, additional, Horakova, Dana, additional, Patti, Francesco, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Girard, Marc, additional, Prat, Alexandre, additional, Lugaresi, Alessandra, additional, Grammond, Pierre, additional, Kalincik, Tomas, additional, Alroughani, Raed, additional, Grand’Maison, Francois, additional, Skibina, Olga, additional, Terzi, Murat, additional, Lechner-Scott, Jeannette, additional, Gerlach, Oliver, additional, Khoury, Samia J., additional, Cartechini, Elisabetta, additional, Van Pesch, Vincent, additional, Sa, Maria Jose, additional, Weinstock-Guttman, Bianca, additional, Blanco, Yolanda, additional, Ampapa, Radek, additional, Spitaleri, Daniele, additional, Solaro, Claudio, additional, Maimone, Davide, additional, Soysal, Aysun, additional, Iuliano, Gerardo, additional, Gouider, Riadh, additional, Castillo-Triviño, Tamara, additional, Sanchez-Menoyo, Jose Luis, additional, van der Walt, Anneke, additional, Oh, Jiwon, additional, Aguera-Morales, Eduardo, additional, Altintas, Ayse, additional, Al-Asmi, Abdullah, additional, de Gans, Koen, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Hodgkinson, Suzanne, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Taylor, Bruce, additional, Gray, Orla, additional, Lalive, Patrice, additional, Rozsa, Csilla, additional, McGuigan, Chris, additional, Kermode, Allan, additional, Perez sempere, Angel, additional, Mihaela, Simu, additional, Simo, Magdolna, additional, Hardy, Todd, additional, Decoo, Danny, additional, Hughes, Stella, additional, Grigoriadis, Nikolaos, additional, Sas, Attila, additional, Vella, Norbert, additional, Moreau, Yves, additional, and Peeters, Liesbet, additional
Published: 2022
Full Text: View/download PDF

21. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

Author: Sharmin, Sifat, primary, Bovis, Francesca, additional, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Trojano, Maria, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grand'Maison, Francois, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Terzi, Murat, additional, Gerlach, Oliver, additional, Alroughani, Raed, additional, Boz, Cavit, additional, Shaygannejad, Vahid, additional, van Pesch, Vincent, additional, Cartechini, Elisabetta, additional, Kappos, Ludwig, additional, Lechner‐Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Turkoglu, Recai, additional, Solaro, Claudio, additional, Iuliano, Gerardo, additional, Granella, Franco, additional, Van Wijmeersch, Bart, additional, Spitaleri, Daniele, additional, Slee, Mark, additional, McCombe, Pamela, additional, Prevost, Julie, additional, Ampapa, Radek, additional, Ozakbas, Serkan, additional, Sanchez‐Menoyo, Jose Luis, additional, Soysal, Aysun, additional, Vucic, Steve, additional, Petersen, Thor, additional, de Gans, Koen, additional, Butler, Ernest, additional, Hodgkinson, Suzanne, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Cristiano, Edgardo, additional, Castillo‐Triviño, Tamara, additional, Saladino, Maria Laura, additional, Barnett, Michael, additional, Moore, Fraser, additional, Rozsa, Csilla, additional, Yamout, Bassem, additional, Skibina, Olga, additional, van der Walt, Anneke, additional, Buzzard, Katherine, additional, Gray, Orla, additional, Hughes, Stella, additional, Sempere, Angel Perez, additional, Singhal, Bhim, additional, Fragoso, Yara, additional, Shaw, Cameron, additional, Kermode, Allan, additional, Taylor, Bruce, additional, Simo, Magdolna, additional, Shuey, Neil, additional, Al‐Harbi, Talal, additional, Macdonell, Richard, additional, Dominguez, Jose Andres, additional, Csepany, Tunde, additional, Sirbu, Carmen Adella, additional, Sormani, Maria Pia, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional
Published: 2022
Full Text: View/download PDF

22. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene Region in Immature Dendritic Cells

Author: Mena, Jorge, Alloza, Iraide, Tulloch Navarro, Raquel, Aldekoa, Ane, Diez Garcia, Javier, Villanueva Etxebarria, Ane, Lindskog, Cecilia, Antiguedad, Alfredo, Boyero, Sabas, Mendibe-Bilbao, Maria del Mar, Alvarez de Arcaya, Amaya, Sanchez Menoyo, Jose Luis, Midaglia, Luciana, Villarrubia, Noelia, Malhotra, Sunny, Montalban, Xavier, Villar, Luisa Maria, Comabella, Manuel, Vandenbroeck, Koen, Mena, Jorge, Alloza, Iraide, Tulloch Navarro, Raquel, Aldekoa, Ane, Diez Garcia, Javier, Villanueva Etxebarria, Ane, Lindskog, Cecilia, Antiguedad, Alfredo, Boyero, Sabas, Mendibe-Bilbao, Maria del Mar, Alvarez de Arcaya, Amaya, Sanchez Menoyo, Jose Luis, Midaglia, Luciana, Villarrubia, Noelia, Malhotra, Sunny, Montalban, Xavier, Villar, Luisa Maria, Comabella, Manuel, and Vandenbroeck, Koen
Abstract: Intronic single-nucleotide polymorphisms (SNPs) in the ANKRD55 gene are associated with the risk for multiple sclerosis (MS) and rheumatoid arthritis by genome-wide association studies (GWAS). The risk alleles have been linked to higher expression levels of ANKRD55 and the neighboring IL6ST (gp130) gene in CD4(+) T lymphocytes of healthy controls. The biological function of ANKRD55, its role in the immune system, and cellular sources of expression other than lymphocytes remain uncharacterized. Here, we show that monocytes gain capacity to express ANKRD55 during differentiation in immature monocyte-derived dendritic cells (moDCs) in the presence of interleukin (IL)-4/granulocyte-macrophage colony-stimulating factor (GM-CSF). ANKRD55 expression levels are further enhanced by retinoic acid agonist AM580 but downregulated following maturation with interferon (IFN)-gamma and lipopolysaccharide (LPS). ANKRD55 was detected in the nucleus of moDC in nuclear speckles. We also analyzed the adjacent IL6ST, IL31RA, and SLC38A9 genes. Of note, in healthy controls, MS risk SNP genotype influenced ANKRD55 and IL6ST expression in immature moDC in opposite directions to that in CD4(+) T cells. This effect was stronger for a partially correlated SNP, rs13186299, that is located, similar to the main MS risk SNPs, in an ANKRD55 intron. Upon analysis in MS patients, the main GWAS MS risk SNP rs7731626 was associated with ANKRD55 expression levels in CD4(+) T cells. MoDC-specific ANKRD55 and IL6ST mRNA levels showed significant differences according to the clinical form of the disease, but, in contrast to healthy controls, were not influenced by genotype. We also measured serum sgp130 levels, which were found to be higher in homozygotes of the protective allele of rs7731626. Our study characterizes ANKRD55 expression in moDC and indicates monocyte-to-dendritic cell (Mo-DC) differentiation as a process potentially influenced by MS risk SNPs.
Published: 2022
Full Text: View/download PDF

23. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

Author: UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Gerlach, Oliver, Alroughani, Raed, Boz, Cavit, Shaygannejad, Vahid, van Pesch, Vincent, Cartechini, Elisabetta, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Iuliano, Gerardo, Granella, Franco, Van Wijmeersch, Bart, Spitaleri, Daniele, Slee, Mark, McCombe, Pamela, Prevost, Julie, Ampapa, Radek, Ozakbas, Serkan, Sanchez-Menoyo, Jose Luis, Soysal, Aysun, Vucic, Steve, Petersen, Thor, de Gans, Koen, Butler, Ernest, Hodgkinson, Suzanne, Sidhom, Youssef, Gouider, Riadh, Cristiano, Edgardo, Castillo-Triviño, Tamara, Saladino, Maria Laura, Barnett, Michael, Moore, Fraser, Rozsa, Csilla, Yamout, Bassem, Skibina, Olga, van der Walt, Anneke, Buzzard, Katherine, Gray, Orla, Hughes, Stella, Sempere, Angel Perez, Singhal, Bhim, Fragoso, Yara, Shaw, Cameron, Kermode, Allan, Taylor, Bruce, Simo, Magdolna, Shuey, Neil, Al-Harbi, Talal, Macdonell, Richard, Dominguez, Jose Andres, Csepany, Tunde, Sirbu, Carmen Adella, Sormani, Maria Pia, Butzkueven, Helmut, Kalincik, Tomas, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Gerlach, Oliver, Alroughani, Raed, Boz, Cavit, Shaygannejad, Vahid, van Pesch, Vincent, Cartechini, Elisabetta, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Iuliano, Gerardo, Granella, Franco, Van Wijmeersch, Bart, Spitaleri, Daniele, Slee, Mark, McCombe, Pamela, Prevost, Julie, Ampapa, Radek, Ozakbas, Serkan, Sanchez-Menoyo, Jose Luis, Soysal, Aysun, Vucic, Steve, Petersen, Thor, de Gans, Koen, Butler, Ernest, Hodgkinson, Suzanne, Sidhom, Youssef, Gouider, Riadh, Cristiano, Edgardo, Castillo-Triviño, Tamara, Saladino, Maria Laura, Barnett, Michael, Moore, Fraser, Rozsa, Csilla, Yamout, Bassem, Skibina, Olga, van der Walt, Anneke, Buzzard, Katherine, Gray, Orla, Hughes, Stella, Sempere, Angel Perez, Singhal, Bhim, Fragoso, Yara, Shaw, Cameron, Kermode, Allan, Taylor, Bruce, Simo, Magdolna, Shuey, Neil, Al-Harbi, Talal, Macdonell, Richard, Dominguez, Jose Andres, Csepany, Tunde, Sirbu, Carmen Adella, Sormani, Maria Pia, Butzkueven, Helmut, and Kalincik, Tomas
Abstract: The prevention of disability over the long term is the main treatment goal in multiple sclerosis (MS); however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained long-term disability worsening. In total, 14,802 6-month confirmed disability progression events were identified in 8741 patients from the global MSBase registry. For each 6-month confirmed progression event (13,321 in the development and 1481 in the validation cohort), a sustained progression score was calculated based on the demographic and clinical characteristics at the time of progression that were predictive of long-term disability worsening. The score was externally validated in the Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) trial. The score was based on age, sex, MS phenotype, relapse activity, disability score and its change from baseline, number of affected functional system domains and worsening in six of the domains. In the internal validation cohort, a 61% lower chance of improvement was estimated with each unit increase in the score (hazard ratio 0.39, 95% confidence interval 0.29-0.52; discriminatory index 0.89). The proportions of progression events sustained at 5 years stratified by the score were 1: 72%; 2: 88%; 3: 94%; 4: 100%. The results of the CLARITY trial were confirmed for reduction of disability progression that was >88% likely to be sustained (events with score ˃1.5). Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.
Published: 2022

24. Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia

Author: Ruisanchez Nieva, Aintzine, Sanchez Menoyo, Jose Luis, Escalza Cortina, Ines, Foncea Beti, Nerea, Gomez Beldarrain, Marian, and Garcia-Monco, Juan Carlos
Published: 2017
Full Text: View/download PDF

25. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Author: Kalincik, Tomas, Manouchehrinia, Ali, Sobisek, Lukas, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Hupperts, Raymond, GrandʼMaison, Francois, Pucci, Eugenio, Boz, Cavit, Alroughani, Raed, Van Pesch, Vincent, Lechner-Scott, Jeannette, Terzi, Murat, Bergamaschi, Roberto, Iuliano, Gerardo, Granella, Franco, Spitaleri, Daniele, Shaygannejad, Vahid, Oreja-Guevara, Celia, Slee, Mark, Ampapa, Radek, Verheul, Freek, McCombe, Pamela, Olascoaga, Javier, Amato, Maria Pia, Vucic, Steve, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Flechter, Shlomo, Cristiano, Edgardo, Rozsa, Csilla, Moore, Fraser, Sanchez-Menoyo, Jose Luis, Saladino, Maria Laura, Barnett, Michael, Hillert, Jan, and Butzkueven, Helmut
Published: 2017
Full Text: View/download PDF

26. sj-docx-1-msj-10.1177_13524585221137502 – Supplemental material for Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Author: Spelman, Tim, Ozakbas, Serkan, Alroughani, Raed, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele LA, van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Al-Asmi, Abdullah, Gerlach, Oliver, Oh, Jiwon, Altintas, Ayse, Tundia, Namita, Wong, Schiffon L, and Butzkueven, Helmut
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, sj-docx-1-msj-10.1177_13524585221137502 for Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry by Tim Spelman, Serkan Ozakbas, Raed Alroughani, Murat Terzi, Suzanne Hodgkinson, Guy Laureys, Tomas Kalincik, Anneke Van Der Walt, Bassem Yamout, Jeannette Lechner-Scott, Aysun Soysal, Jens Kuhle, Jose Luis Sanchez-Menoyo, Yolanda Blanco Morgado, Daniele LA Spitaleri, Vincent van Pesch, Dana Horakova, Radek Ampapa, Francesco Patti, Richard Macdonell, Abdullah Al-Asmi, Oliver Gerlach, Jiwon Oh, Ayse Altintas, Namita Tundia, Schiffon L Wong and Helmut Butzkueven in Multiple Sclerosis Journal
Published: 2022
Full Text: View/download PDF

27. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Author: Rojas, Juan Ignacio, Gray, Orla, Khurana, Dheeraj, Van Wijmeersch, Bart, Grigoriadis, Nikolaos, Inshasi, Jihad, Oh, Jiwon, Aguera-Morales, Eduardo, Fragoso, Yara, Moore, Fraser, Shaw, Cameron, Baghbanian, Seyed Mohammad, Shuey, Neil, Willekens, Barbara, Hardy, Todd A., Decoo, Danny, Sempere, Angel Perez, Field, Deborah, Wynford-Thomas, Ray, Cunniffe, Nick G., Roos, Izanne, Malpas, Charles B., Coles, Alasdair J., Kalincik, Tomas, Brown, J. William L., MSBase Study Grp, MSBase Study Grp, Shaygannejad, Vahid, Daruwalla, Cyrus, ÖZAKBAŞ, SERKAN, Havrdova, Eva Kubala, Horakova, Dana, Alroughani, Raed, BOZ, CAVİT, Patti, Francesco, Onofrj, Marco, Lugaresi, Alessandra, Eichau, Sara, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Yamout, Bassem, Khoury, Samia J., Sajedi, Seyed Aidin, Turkoglu, Recai, Altintas, Ayse, Skibina, Olga, Buzzard, Katherine, Grammond, Pierre, Karabudak, Rana, van der Walt, Anneke, Butzkueven, Helmut, Maimone, Davide, Lechner-Scott, Jeannette, Soysal, Aysun, John, Nevin, Prevost, Julie, Spitaleri, Daniele, Ramo-Tello, Cristina, Gerlach, Oliver, Iuliano, Gerardo, Foschi, Matteo, Ampapa, Radek, van Pesch, Vincent, Barnett, Michael, Shalaby, Nevin, D'hooghe, Marie, Kuhle, Jens, Sa, Maria Jose, Fabis-Pedrini, Marzena, Kermode, Allan, Mrabet, Saloua, Gouider, Riadh, Hodgkinson, Suzanne, Laureys, Guy, Van Hijfte, Liesbeth, Macdonell, Richard, Oreja-Guevara, Celia, Cristiano, Edgardo, McCombe, Pamela, Sanchez-Menoyo, Jose Luis, Singhal, Bhim, Blanco, Yolanda, Hughes, Stella, Garber, Justin, Solaro, Claudio, McGuigan, Chris, Taylor, Bruce, de Gans, Koen, Habek, Mario, Al-Asmi, Abdullah, Mihaela, Simu, Castillo Trivino, Tamara, Al-Harbi, Talal, MSBase Study Group, Clinical sciences, Neuroprotection & Neuromodulation, Neurology, Faculty of Medicine and Pharmacy, Daruwalla, Cyrus [0000-0002-2329-5329], Shaygannejad, Vahid [0000-0001-5511-509X], Horakova, Dana [0000-0003-1915-0036], Alroughani, Raed [0000-0001-5436-5804], Patti, Francesco [0000-0002-6923-0846], Lugaresi, Alessandra [0000-0003-2902-5589], Eichau, Sara [0000-0001-9159-3128], Duquette, Pierre [0000-0001-7231-1754], Sajedi, Seyed Aidin [0000-0002-6704-9787], van der Walt, Anneke [0000-0002-4278-7003], Lechner-Scott, Jeannette [0000-0002-3850-447X], Barnett, Michael [0000-0002-2156-8864], Oreja-Guevara, Celia [0000-0002-9221-5716], Habek, Mario [0000-0002-3360-1748], Castillo Triviño, Tamara [0000-0002-9249-3185], Inshasi, Jihad [0000-0001-5892-751X], Oh, Jiwon [0000-0001-5519-6088], Fragoso, Yara [0000-0001-8726-089X], Baghbanian, Seyed Mohammad [0000-0002-8138-7504], Hardy, Todd A [0000-0003-4145-3172], Decoo, Danny [0000-0001-7689-3114], Roos, Izanne [0000-0003-0371-3666], Kalincik, Tomas [0000-0003-3778-1376], Brown, J William L [0000-0002-7737-5834], Apollo - University of Cambridge Repository, and UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire
Subjects: Neuroscience(all), Multiple sclerosis, prognosis, multiple sclerosis, Prognosis, Multiple Sclerosis, Relapsing-Remitting, Neurology, Recurrence, Medicine and Health Sciences, Humans, Human medicine, Neurology (clinical)
Abstract: Background: The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear. Objective: To determine whether early non-disabling relapses predict disability accumulation in RRMS. Methods: We redefined mild relapses in MSBase as ‘non-disabling’, and moderate or severe relapses as ‘disabling’. We used mixed-effects Cox models to compare 90-day confirmed disability accumulation events in people with exclusively non-disabling relapses within 2 years of RRMS diagnosis to those with no early relapses; and any early disabling relapses. Analyses were stratified by disease-modifying therapy (DMT) efficacy during follow-up. Results: People who experienced non-disabling relapses within 2 years of RRMS diagnosis accumulated more disability than those with no early relapses if they were untreated ( n = 285 vs 4717; hazard ratio (HR) = 1.29, 95% confidence interval (CI) = 1.00–1.68) or given platform DMTs ( n = 1074 vs 7262; HR = 1.33, 95% CI = 1.15–1.54), but not if given high-efficacy DMTs ( n = 572 vs 3534; HR = 0.90, 95% CI = 0.71–1.13) during follow-up. Differences in disability accumulation between those with early non-disabling relapses and those with early disabling relapses were not confirmed statistically. Conclusion: This study suggests that early non-disabling relapses are associated with a higher risk of disability accumulation than no early relapses in RRMS. This risk may be mitigated by high-efficacy DMTs. Therefore, non-disabling relapses should be considered when making treatment decisions.
Published: 2023

28. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]

Author: De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, Sá, Maria José, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannejad, Vahid, Moore, Fraser, Oreja-Guevara, Celia, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, and Peeters, Liesbet
Published: 2022
Full Text: View/download PDF

29. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.

Author: Spelman, Tim, Ozakbas, Serkan, Alroughani, Raed, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele LA, van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, and Macdonell, Richard
Subjects: ORAL drug administration, MULTIPLE sclerosis, DIMETHYL fumarate, TERMINATION of treatment, TREATMENT effectiveness
Abstract: Background: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience. Objectives: Use real-world data to compare treatment patterns and clinical outcomes in people with MS (pwMS) treated with cladribine tablets versus other oral DMTs. Methods: Retrospective treatment comparisons were based on data from the international MSBase registry. Eligible pwMS started treatment with cladribine, fingolimod, dimethyl fumarate, or teriflunomide tablets from 2018 to mid-2021 and were censored at treatment discontinuation/switch, death, loss to follow-up, pregnancy, or study period end. Treatment persistence was evaluated as time to discontinuation/switch; relapse outcomes included time to first relapse and annualized relapse rate (ARR). Results: Cohorts included 633 pwMS receiving cladribine tablets, 1195 receiving fingolimod, 912 receiving dimethyl fumarate, and 735 receiving teriflunomide. Individuals treated with fingolimod, dimethyl fumarate, or teriflunomide switched treatment significantly more quickly than matched cladribine tablet cohorts (adjusted hazard ratio (95% confidence interval): 4.00 (2.54–6.32), 7.04 (4.16–11.93), and 6.52 (3.79–11.22), respectively). Cladribine tablet cohorts had significantly longer time-to-treatment discontinuation, time to first relapse, and lower ARR, compared with other oral DMT cohorts. Conclusion: Cladribine tablets were associated with a significantly greater real-world treatment persistence and more favorable relapse outcomes than all oral DMT comparators. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

30. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

Author: Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, Butzkueven, Helmut, MSBase Study Group, UCL - (SLuc) Service de neurologie, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Kalincik, Toma, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charle, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francoi, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Lui, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, and Butzkueven, Helmut
Subjects: Adult, Male, medicine.medical_specialty, Article, 03 medical and health sciences, Disability Evaluation, 0302 clinical medicine, Natalizumab, Multiple Sclerosis, Relapsing-Remitting, multiple sclerosis, treatment, prognosis, Internal medicine, medicine, Humans, Immunologic Factors, Disease Progression, Female, Fingolimod Hydrochloride, Glatiramer Acetate, Immunosuppressive Agents, Interferon-beta, Longitudinal Studies, Middle Aged, Proportional Hazards Models, 030212 general & internal medicine, Glatiramer acetate, Expanded Disability Status Scale, Proportional hazards model, business.industry, Multiple sclerosis, Hazard ratio, medicine.disease, Confidence interval, Cohort, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
Abstract: ObjectiveTo test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients.MethodsWe studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity.ResultsA total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43–0.82, p = 0.0016), worsening of disability (0.56, 0.38–0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19–0.59, p = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50–0.70, p = 10−9) and worsening of disability (0.81, 0.67–0.99, p = 0.043).ConclusionContinued treatment with MS immunotherapies reduces disability accrual by 19%–44% (95% CI 1%–62%), the risk of need of a walking aid by 67% (95% CI 41%–81%), and the frequency of relapses by 40–41% (95% CI 18%–57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term.Classification of EvidenceThis study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
Published: 2021

31. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Author: UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, Butzkueven, Helmut, MSBase Study Group, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de neurologie, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Kalincik, Tomas, Diouf, Ibrahima, Sharmin, Sifat, Malpas, Charles, Spelman, Tim, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Jokubaitis, Vilija, van der Walt, Anneke, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, Raymond, Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Van Pesch, Vincent, Granella, Franco, Bergamaschi, Roberto, Spitaleri, Daniele, Slee, Mark, Vucic, Steve, Ampapa, Radek, McCombe, Pamela, Ramo-Tello, Cristina, Prevost, Julie, Olascoaga, Javier, Cristiano, Edgardo, Barnett, Michael, Saladino, Maria Laura, Sanchez-Menoyo, Jose Luis, Hodgkinson, Suzanne, Rozsa, Csilla, Hughes, Stella, Moore, Fraser, Shaw, Cameron, Butler, Ernest, Skibina, Olga, Gray, Orla, Kermode, Allan, Csepany, Tunde, Singhal, Bhim, Shuey, Neil, Piroska, Imre, Taylor, Bruce, Simo, Magdolna, Sirbu, Carmen-Adella, Sas, Attila, Butzkueven, Helmut, and MSBase Study Group
Abstract: To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year, and exposed to MS therapy, and a subset of patients with ≥15-year follow-up. Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. Marginal structural models were continuously readjusted for patient age, sex, pregnancy, date, disease course, time from first symptom, prior relapse history, disability, and MRI activity. A total of 14,717 patients were studied. During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43-0.82, = 0.0016), worsening of disability (0.56, 0.38-0.82, = 0.0026), and progress to EDSS step 6 (0.33, 0.19-0.59, = 0.00019). Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, = 10) and worsening of disability (0.81, 0.67-0.99, = 0.043). Continued treatment with MS immunotherapies reduces disability accrual by 19%-44% (95% CI 1%-62%), the risk of need of a walking aid by 67% (95% CI 41%-81%), and the frequency of relapses by 40-41% (95% CI 18%-57%) over 15 years. This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. This study provides Class IV evidence that, for patients with relapsing-remitting MS, long-term exposure to immunotherapy prevents neurologic disability.
Published: 2021

32. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.

Author: UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, José Sá, Maria, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannejad, Vahid, Moore, Fraser, Oreja-Guevara, Celia, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, Peeters, Liesbet, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, José Sá, Maria, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannejad, Vahid, Moore, Fraser, Oreja-Guevara, Celia, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, and Peeters, Liesbet
Abstract: Research in Multiple Sclerosis (MS) has recently focused on extracting knowledge from real-world clinical data sources. This type of data is more abundant than data produced during clinical trials and potentially more informative about real-world clinical practice. However, this comes at the cost of less curated and controlled data sets. In this work we aim to predict disability progression by optimally extracting information from longitudinal patient data in the real-world setting, with a special focus on the sporadic sampling problem. We use machine learning methods suited for patient trajectories modeling, such as recurrent neural networks and tensor factorization. A subset of 6682 patients from the MSBase registry is used. We can predict disability progression of patients in a two-year horizon with an ROC-AUC of 0.85, which represents a 32% decrease in the ranking pair error (1-AUC) compared to reference methods using static clinical features. Compared to the models available in the literature, this work uses the most complete patient history for MS disease progression prediction and represents a step forward towards AI-assisted precision medicine in MS.
Published: 2021

33. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Author: Diouf, Ibrahima, primary, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Patti, Francesco, additional, Shaygannejad, Vahid, additional, Ozakbas, Serkan, additional, Ayuso, Guillermo Izquierdo, additional, Madueño, Sara Eichau, additional, Zakaria, Magd, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Hamdy, Sherif, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Turkoglu, Recai, additional, Butzkueven, Helmut, additional, Yamout, Bassem, additional, Altintas, Ayse, additional, Van Pesch, Vincent, additional, Maimone, Davide, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Karabudak, Rana, additional, Iuliano, Gerardo, additional, McGuigan, Christopher, additional, Cartechini, Elisabetta, additional, Barnett, Michael, additional, Hughes, Stella, additional, Sa, Maria Jose, additional, Kappos, Ludwig, additional, Ramo-Tello, Cristina, additional, Cristiano, Edgardo, additional, Hodgkinson, Suzanne, additional, Spitaleri, Daniele Litterio A., additional, Soysal, Aysun, additional, Petersen, Thor, additional, Slee, Mark, additional, Butler, Ernest, additional, Granella, Franco, additional, Verheul, Freek, additional, McCombe, Pamela, additional, Ampapa, Radek, additional, Skibina, Olga, additional, Prevost, Julie, additional, Sinnige, L, additional, Sanchez-Menoyo, Jose Luis, additional, Vucic, Steve, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Khurana, Dheeraj, additional, Macdonell, Richard, additional, Castillo-Triviño, Tamara, additional, Gray, Orla, additional, Aguera-Morales, Eduardo, additional, Kister, Ilya, additional, Shaw, Cameron, additional, Deri, Norma, additional, Al-Harbi, Talal, additional, Fragoso, Yara, additional, Csepany, Tunde, additional, Sempere, Angel, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

34. Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)

Author: Vitkova, Marianna, primary, Diouf, Ibrahima, additional, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva Kubala, additional, Patti, Francesco, additional, Ozakbas, Serkan, additional, Ayuso, Guillermo Izquierdo, additional, Madueño, Sara Eichau, additional, Shaygannejad, Vahid, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Alroughani, Raed, additional, Prat, Alexandre, additional, Larochelle, Catherine, additional, Girard, Marc, additional, Duquette, Pierre, additional, Terzi, Murat, additional, Boz, Cavit, additional, Grand’Maison, Francois, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Butzkueven, Helmut, additional, Buzzard, Katherine, additional, Skibina, Olga, additional, Yamout, Bassem, additional, Karabudak, Rana, additional, Gerlach, Oliver H.H, additional, Lechner-Scott, Jeannette, additional, Maimone, Davide, additional, Bergamaschi, Roberto, additional, Van Pesch, Vincent, additional, Iuliano, Gerardo, additional, Cartechini, Elisabetta, additional, Sá, Maria José, additional, Ampapa, Radek, additional, Barnett, Michael, additional, Hughes, Stella, additional, Ramo-Tello, Cristina, additional, Hodgkinson, Suzanne, additional, Spitareli, Daniele, additional, Petersen, Thor, additional, Butler, Ernest, additional, Slee, Mark, additional, McGuigan, Christopher, additional, McCombe, Pamela, additional, Granella, Franco, additional, Cristiano, Edgardo, additional, Prevost, Julie, additional, Taylor, Bruce, additional, Sanchez-Menoyo, Jose Luis, additional, Laureys, Guy, additional, Van Hijfte, Liesbeth, additional, Vucic, Steve, additional, Macdonell, Richard, additional, Gray, Orla, additional, Urtaza, Francisco Javier Olascoaga, additional, Deri, Norma, additional, Fragoso, Yara, additional, Shaw, Cameron, additional, and Kalincik, Tomas, additional
Published: 2021
Full Text: View/download PDF

35. MSJ926955_supplementary_material – Supplemental material for Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Author: Le, Minh, Malpas, Charles, Sifat Sharmin, Horáková, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Larochelle, Catherine, Alroughani, Raed, Bergamaschi, Roberto, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Francois Grand’ Maison, Terzi, Murat, Boz, Cavit, Hupperts, Raymond, Butzkueven, Helmut, Pucci, Eugenio, Granella, Franco, Pesch, Vincent Van, Soysal, Aysun, Yamout, Bassem I., Lechner-Scott, Jeannette, Spitaleri, Daniele LA, Ampapa, Radek, Turkoglu, Recai, Iuliano, Gerardo, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Sidhom, Youssef, Gouider, Riadh, Shaygannejad, Vahid, Prevost, Julie, Ayse Altintas, Fragoso, Yara Dadalti, McCombe, Pamela Ann, Petersen, Thor, Slee, Mark, Barnett, Michael H, Vucic, Steve, Walt, Anneke Van Der, and Kalincik, Tomas
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, MSJ926955_supplementary_material for Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis by Minh Le, Charles Malpas, Sifat Sharmin, Dana Horáková, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Catherine Larochelle, Raed Alroughani, Roberto Bergamaschi, Patrizia Sola, Diana Ferraro, Pierre Grammond, Francois Grand’ Maison, Murat Terzi, Cavit Boz, Raymond Hupperts, Helmut Butzkueven, Eugenio Pucci, Franco Granella, Vincent Van Pesch, Aysun Soysal, Bassem I. Yamout, Jeannette Lechner-Scott, Daniele LA Spitaleri, Radek Ampapa, Recai Turkoglu, Gerardo Iuliano, Cristina Ramo-Tello, Jose Luis Sanchez-Menoyo, Youssef Sidhom, Riadh Gouider, Vahid Shaygannejad, Julie Prevost, Ayse Altintas, Yara Dadalti Fragoso, Pamela Ann McCombe, Thor Petersen, Mark Slee, Michael H Barnett, Steve Vucic, Anneke Van Der Walt and Tomas Kalincik in Multiple Sclerosis Journal
Published: 2020
Full Text: View/download PDF

36. MSJ936823_supplement – Supplemental material for Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score

Author: Kunchok, Amy, Lechner-Scott, Jeannette, Granella, Franco, Trojano, Maria, Alroughani, Raed, Sola, Patrizia, Ferraro, Diana, Lugaresi, Alessandra, Onofrj, Marco, Ozakbas, Serkan, Izquierdo, Guillermo, Grammond, Pierre, Sanchez-Menoyo, Jose Luis, Wijmeersch, Bart Van, Boz, Cavit, Pucci, Eugenio, McCombe, Pamela, Francois Grand’Maison, Spitaleri, Daniele, Vucic, Steve, Hupperts, Raymond, Jokubaitis, Vilija, Sormani, Maria Pia, Butzkueven, Helmut, and Kalincik, Tomas
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, MSJ936823_supplement for Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score by Amy Kunchok, Jeannette Lechner-Scott, Franco Granella, Maria Trojano, Raed Alroughani, Patrizia Sola, Diana Ferraro, Alessandra Lugaresi, Marco Onofrj, Serkan Ozakbas, Guillermo Izquierdo, Pierre Grammond, Jose Luis Sanchez-Menoyo, Bart Van Wijmeersch, Cavit Boz, Eugenio Pucci, Pamela McCombe, Francois Grand’Maison, Daniele Spitaleri, Steve Vucic, Raymond Hupperts, Vilija Jokubaitis, Maria Pia Sormani, Helmut Butzkueven and Tomas Kalincik in Multiple Sclerosis Journal
Published: 2020
Full Text: View/download PDF

37. Risk of secondary progressive multiple sclerosis: A longitudinal study.

Author: UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Fambiatos, Adam, Jokubaitis, Vilija, Horakova, Dana, Kubala Havrdova, Eva, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Bergamaschi, Roberto, Van Pesch, Vincent, Ozakbas, Serkan, Granella, Franco, Turkoglu, Recai, Iuliano, Gerardo, Spitaleri, Daniele, McCombe, Pamela, Solaro, Claudio, Slee, Mark, Ampapa, Radek, Soysal, Aysun, Petersen, Thor, Sanchez-Menoyo, Jose Luis, Verheul, Freek, Prevost, Julie, Sidhom, Youssef, Van Wijmeersch, Bart, Vucic, Steve, Cristiano, Edgardo, Saladino, Maria Laura, Deri, Norma, Barnett, Michael, Olascoaga, Javier, Moore, Fraser, Skibina, Olga, Gray, Orla, Fragoso, Yara, Yamout, Bassem, Shaw, Cameron, Singhal, Bhim, Shuey, Neil, Hodgkinson, Suzanne, Altintas, Ayse, Al-Harbi, Talal, Csepany, Tunde, Taylor, Bruce, Hughes, Jordana, Jun, Jae-Kwan, van der Walt, Anneke, Spelman, Tim, Butzkueven, Helmut, Kalincik, Tomas, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Fambiatos, Adam, Jokubaitis, Vilija, Horakova, Dana, Kubala Havrdova, Eva, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Bergamaschi, Roberto, Van Pesch, Vincent, Ozakbas, Serkan, Granella, Franco, Turkoglu, Recai, Iuliano, Gerardo, Spitaleri, Daniele, McCombe, Pamela, Solaro, Claudio, Slee, Mark, Ampapa, Radek, Soysal, Aysun, Petersen, Thor, Sanchez-Menoyo, Jose Luis, Verheul, Freek, Prevost, Julie, Sidhom, Youssef, Van Wijmeersch, Bart, Vucic, Steve, Cristiano, Edgardo, Saladino, Maria Laura, Deri, Norma, Barnett, Michael, Olascoaga, Javier, Moore, Fraser, Skibina, Olga, Gray, Orla, Fragoso, Yara, Yamout, Bassem, Shaw, Cameron, Singhal, Bhim, Shuey, Neil, Hodgkinson, Suzanne, Altintas, Ayse, Al-Harbi, Talal, Csepany, Tunde, Taylor, Bruce, Hughes, Jordana, Jun, Jae-Kwan, van der Walt, Anneke, Spelman, Tim, Butzkueven, Helmut, and Kalincik, Tomas
Abstract: BACKGROUND: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. OBJECTIVE: The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. METHODS: Patients with adult-onset relapsing-remitting multiple sclerosis and at least four recorded disability scores were selected from MSBase, a global observational cohort. The risk of conversion to objectively defined secondary progressive multiple sclerosis was evaluated at multiple time points per patient using multivariable marginal Cox regression models. Sensitivity analyses were performed. RESULTS: A total of 15,717 patients were included in the primary analysis. Older age (hazard ratio (HR) = 1.02, p < 0.001), longer disease duration (HR = 1.01, p = 0.038), a higher Expanded Disability Status Scale score (HR = 1.30, p < 0.001), more rapid disability trajectory (HR = 2.82, p < 0.001) and greater number of relapses in the previous year (HR = 1.07, p = 0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR = 0.62, p = 0.039) and disease-modifying therapy exposure (HR = 0.71, p = 0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. CONCLUSION: Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.
Published: 2020

38. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

Author: Le, Minh, primary, Malpas, Charles, additional, Sharmin, Sifat, additional, Horáková, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Izquierdo, Guillermo, additional, Eichau, Sara, additional, Ozakbas, Serkan, additional, Lugaresi, Alessandra, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Larochelle, Catherine, additional, Alroughani, Raed, additional, Bergamaschi, Roberto, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Grammond, Pierre, additional, Grand’ Maison, Francois, additional, Terzi, Murat, additional, Boz, Cavit, additional, Hupperts, Raymond, additional, Butzkueven, Helmut, additional, Pucci, Eugenio, additional, Granella, Franco, additional, Van Pesch, Vincent, additional, Soysal, Aysun, additional, Yamout, Bassem I., additional, Lechner-Scott, Jeannette, additional, Spitaleri, Daniele LA, additional, Ampapa, Radek, additional, Turkoglu, Recai, additional, Iuliano, Gerardo, additional, Ramo-Tello, Cristina, additional, Sanchez-Menoyo, Jose Luis, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Shaygannejad, Vahid, additional, Prevost, Julie, additional, Altintas, Ayse, additional, Fragoso, Yara Dadalti, additional, McCombe, Pamela Ann, additional, Petersen, Thor, additional, Slee, Mark, additional, Barnett, Michael H, additional, Vucic, Steve, additional, Van Der Walt, Anneke, additional, and Kalincik, Tomas, additional
Published: 2020
Full Text: View/download PDF

39. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

Author: Sharmin, Sifat, primary, Bovis, Francesca, additional, Malpas, Charles, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Ayuso, Guillermo Izquierdo, additional, Eichau, Sara, additional, Trojano, Maria, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Onofrj, Marco, additional, Lugaresi, Alessandra, additional, Grand’Maison, Francois, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Terzi, Murat, additional, Hupperts, R.M.M., additional, Alroughani, Raed, additional, Boz, Cavit, additional, Shaygannejad, Vijay, additional, Van Pesch, Vincent, additional, Kappos, Ludwig, additional, Lechner-Scott, Jeannette, additional, Bergamaschi, Roberto, additional, Turkoglu, Recai, additional, Solaro, Claudio, additional, Ramo-Tello, Cristina, additional, Iuliano, Gerardo, additional, Granella, Franco, additional, Van Wijmeersch, Bart, additional, Spitaleri, Daniele Litterio A., additional, Bolanos, Ricardo Fernandez, additional, Slee, Mark, additional, McCombe, Pamela, additional, Prevost, Julie, additional, Ampapa, Radek, additional, Ozakbas, Serkan, additional, Sanchez-Menoyo, Jose Luis, additional, Soysal, Aysun, additional, Vucic, Ostoja (Steve), additional, Petersen, Thor, additional, Verheul, Freek, additional, Butler, Ernest, additional, Hodgkinson, Suzanne, additional, Sidhom, Youssef, additional, Gouider, Riadh, additional, Cristiano, Edgardo, additional, Urtaza, Francisco Javier Olascoaga, additional, Saladino, Maria Laura, additional, Barnett, Michael, additional, Deri, Norma, additional, Moore, Fraser, additional, Rozsa, Csilla, additional, Yamout, Bassem, additional, Skibina, Olga, additional, Gray, Orla, additional, Campbell, Jamie, additional, Sempere, Angel, additional, Singhal, Bhim, additional, Fragoso, Yara, additional, Shaw, Cameron, additional, Kermode, Allan, additional, Petkovska-Boskova, Tatjana, additional, Taylor, Bruce, additional, Simo, Magdolna, additional, Vella, Norbert, additional, Shuey, Neil, additional, Alkhaboori, Jabir, additional, Al-Harbi, Talal, additional, Macdonell, Richard, additional, Dominguez, Jose Andres, additional, Kister, Ilya, additional, Csepany, Tunde, additional, Vrech, Carlos, additional, Kovacs, Krisztina, additional, Sirbu, Carmen Adella, additional, Hughes, Stella, additional, Sormani, Maria Pia, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional
Published: 2020
Full Text: View/download PDF

40. MSJ868990_online_supplement – Supplemental material for Risk of secondary progressive multiple sclerosis: A longitudinal study

Author: Fambiatos, Adam, Jokubaitis, Vilija, Horakova, Dana, Havrdova, Eva Kubala, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo, Francois Grand’Maison, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Bergamaschi, Roberto, Pesch, Vincent Van, Ozakbas, Serkan, Granella, Franco, Turkoglu, Recai, Iuliano, Gerardo, Spitaleri, Daniele, McCombe, Pamela, Solaro, Claudio, Slee, Mark, Ampapa, Radek, Soysal, Aysun, Petersen, Thor, Sanchez-Menoyo, Jose Luis, Verheul, Freek, Prevost, Julie, Sidhom, Youssef, Wijmeersch, Bart Van, Vucic, Steve, Cristiano, Edgardo, Saladino, Maria Laura, Deri, Norma, Barnett, Michael, Olascoaga, Javier, Moore, Fraser, Skibina, Olga, Gray, Orla, Fragoso, Yara, Yamout, Bassem, Shaw, Cameron, Bhim Singhal, Shuey, Neil, Hodgkinson, Suzanne, Ayse Altintas, Al-Harbi, Talal, Tunde Csepany, Taylor, Bruce, Hughes, Jordana, Jun, Jae-Kwan, Walt, Anneke Van Der, Spelman, Tim, Butzkueven, Helmut, and Kalincik, Tomas
Subjects: FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract: Supplemental material, MSJ868990_online_supplement for Risk of secondary progressive multiple sclerosis: A longitudinal study by Adam Fambiatos, Vilija Jokubaitis, Dana Horakova, Eva Kubala Havrdova, Maria Trojano, Alexandre Prat, Marc Girard, Pierre Duquette, Alessandra Lugaresi, Guillermo Izquierdo, Francois Grand’Maison, Pierre Grammond, Patrizia Sola, Diana Ferraro, Raed Alroughani, Murat Terzi, Raymond Hupperts, Cavit Boz, Jeannette Lechner-Scott, Eugenio Pucci, Roberto Bergamaschi, Vincent Van Pesch, Serkan Ozakbas, Franco Granella, Recai Turkoglu, Gerardo Iuliano, Daniele Spitaleri, Pamela McCombe, Claudio Solaro, Mark Slee, Radek Ampapa, Aysun Soysal, Thor Petersen, Jose Luis Sanchez-Menoyo, Freek Verheul, Julie Prevost, Youssef Sidhom, Bart Van Wijmeersch, Steve Vucic, Edgardo Cristiano, Maria Laura Saladino, Norma Deri, Michael Barnett, Javier Olascoaga, Fraser Moore, Olga Skibina, Orla Gray, Yara Fragoso, Bassem Yamout, Cameron Shaw, Bhim Singhal, Neil Shuey, Suzanne Hodgkinson, Ayse Altintas, Talal Al-Harbi, Tunde Csepany, Bruce Taylor, Jordana Hughes, Jae-Kwan Jun, Anneke van der Walt, Tim Spelman, Helmut Butzkueven and Tomas Kalincik in Multiple Sclerosis Journal
Published: 2019
Full Text: View/download PDF

41. Risk of secondary progressive multiple sclerosis: A longitudinal study

Author: Fambiatos, Adam, primary, Jokubaitis, Vilija, additional, Horakova, Dana, additional, Kubala Havrdova, Eva, additional, Trojano, Maria, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Lugaresi, Alessandra, additional, Izquierdo, Guillermo, additional, Grand’Maison, Francois, additional, Grammond, Pierre, additional, Sola, Patrizia, additional, Ferraro, Diana, additional, Alroughani, Raed, additional, Terzi, Murat, additional, Hupperts, Raymond, additional, Boz, Cavit, additional, Lechner-Scott, Jeannette, additional, Pucci, Eugenio, additional, Bergamaschi, Roberto, additional, Van Pesch, Vincent, additional, Ozakbas, Serkan, additional, Granella, Franco, additional, Turkoglu, Recai, additional, Iuliano, Gerardo, additional, Spitaleri, Daniele, additional, McCombe, Pamela, additional, Solaro, Claudio, additional, Slee, Mark, additional, Ampapa, Radek, additional, Soysal, Aysun, additional, Petersen, Thor, additional, Sanchez-Menoyo, Jose Luis, additional, Verheul, Freek, additional, Prevost, Julie, additional, Sidhom, Youssef, additional, Van Wijmeersch, Bart, additional, Vucic, Steve, additional, Cristiano, Edgardo, additional, Saladino, Maria Laura, additional, Deri, Norma, additional, Barnett, Michael, additional, Olascoaga, Javier, additional, Moore, Fraser, additional, Skibina, Olga, additional, Gray, Orla, additional, Fragoso, Yara, additional, Yamout, Bassem, additional, Shaw, Cameron, additional, Singhal, Bhim, additional, Shuey, Neil, additional, Hodgkinson, Suzanne, additional, Altintas, Ayse, additional, Al-Harbi, Talal, additional, Csepany, Tunde, additional, Taylor, Bruce, additional, Hughes, Jordana, additional, Jun, Jae-Kwan, additional, van der Walt, Anneke, additional, Spelman, Tim, additional, Butzkueven, Helmut, additional, and Kalincik, Tomas, additional
Published: 2019
Full Text: View/download PDF

42. Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

Author: Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, Di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Vitetta, Francesca, Simone, Anna Maria, Haartsen, Jodi, Spelman, Tim, Marriott, Mark, Kilpatrick, Trevor, King, John, Buzzard, Katherine, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Brown, J William L, Kunchok, Amy, Diamanti, Matteo, Cartechini, Elisabetta, Curti, Erica, Tsantes, Elena, Zwanikken, Cees, Rio, Maria Edite, Hughes, Stella, Amato, Maria Pita, Van Wijmeersch, Bart, Sanchez-Menoyo, Jose Luis, Bolaños, Ricardo Fernandez, Sajedi, Seyed Aidin, Iuliano, Gerardo, Den Braber-Moerland, Leontien, Prevost, Julie, Sempere, Angel Perez, Sidhom, Youssef, Butler, Ernest, Vucic, Steve, Taylor, Bruce, Cabrera-Gomez, Jose Antonio, Oreja-Guevara, Celia, Bergamaschi, Roberto, Turkoglu, Recai, Olascoaga, Javier, Cristiano, Edgardo, Rojas, Juan Ingacio, Hodgkinson, Suzanne, Skibina, Olga, Al-Harbi, Talal, Altintas, Ayse, McCombe, Pamela, Sinnige, LGF, Ozakbas, Serken, Saladino, Maria Laura, Bacile, Elizabeth Alejandra, Vrech, Carlos, Shaw, Cameron, Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, Di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Vitetta, Francesca, Simone, Anna Maria, Haartsen, Jodi, Spelman, Tim, Marriott, Mark, Kilpatrick, Trevor, King, John, Buzzard, Katherine, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Brown, J William L, Kunchok, Amy, Diamanti, Matteo, Cartechini, Elisabetta, Curti, Erica, Tsantes, Elena, Zwanikken, Cees, Rio, Maria Edite, Hughes, Stella, Amato, Maria Pita, Van Wijmeersch, Bart, Sanchez-Menoyo, Jose Luis, Bolaños, Ricardo Fernandez, Sajedi, Seyed Aidin, Iuliano, Gerardo, Den Braber-Moerland, Leontien, Prevost, Julie, Sempere, Angel Perez, Sidhom, Youssef, Butler, Ernest, Vucic, Steve, Taylor, Bruce, Cabrera-Gomez, Jose Antonio, Oreja-Guevara, Celia, Bergamaschi, Roberto, Turkoglu, Recai, Olascoaga, Javier, Cristiano, Edgardo, Rojas, Juan Ingacio, Hodgkinson, Suzanne, Skibina, Olga, Al-Harbi, Talal, Altintas, Ayse, McCombe, Pamela, Sinnige, LGF, Ozakbas, Serken, Saladino, Maria Laura, Bacile, Elizabeth Alejandra, Vrech, Carlos, and Shaw, Cameron
Published: 2018

43. Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.

Author: UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Min, Myintzu, Spelman, Tim, Lugaresi, Alessandra, Boz, Cavit, Spitaleri, Daniele LA, Pucci, Eugenio, Grand'Maison, Francois, Granella, Franco, Izquierdo, Guillermo, Butzkueven, Helmut, Sanchez-Menoyo, Jose Luis, Barnett, Michael, Girard, Marc, Trojano, Maria, Grammond, Pierre, Duquette, Pierre, Sola, Patrizia, Alroughani, Raed, Hupperts, Raymond, Vucic, Steve, Kalincik, Tomas, Van Pesch, Vincent, Lechner-Scott, Jeannette, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, Min, Myintzu, Spelman, Tim, Lugaresi, Alessandra, Boz, Cavit, Spitaleri, Daniele LA, Pucci, Eugenio, Grand'Maison, Francois, Granella, Franco, Izquierdo, Guillermo, Butzkueven, Helmut, Sanchez-Menoyo, Jose Luis, Barnett, Michael, Girard, Marc, Trojano, Maria, Grammond, Pierre, Duquette, Pierre, Sola, Patrizia, Alroughani, Raed, Hupperts, Raymond, Vucic, Steve, Kalincik, Tomas, Van Pesch, Vincent, and Lechner-Scott, Jeannette
Abstract: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions. A total of 8311 MRI brain scans of 4232 patients were identified. Around 26.9% (336/1247) MRIs with one new T2 lesion were followed by disease-modifying therapy (DMT) change, increasing to 50.2% (129/257) with six new T2 lesions. DMT change was twice as likely with new T1 contrast enhancing compared to new T2 lesions odds ratio (OR): 2.43, 95% confidence interval (CI): 2.00-2.96 vs OR: 1.26 (95% CI: 1.22-1.29). DMT change with new MRI lesions occurred most frequently with 'injectable' DMTs. The probability of switching therapy was greater only after high-efficacy therapies became available in 2007 (after, OR: 1.43, 95% CI: 1.28-1.59 vs before, OR: 0.98, 95% CI: 0.520-1.88). MS clinicians rely increasingly on MRI alone in their treatment decisions, utilizing low thresholds (1 new T2 lesion) for optimizing MS therapy. This signals a shift towards no evidence of disease activity (NEDA)-3 since high-efficacy therapies became available.
Published: 2018

44. Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis

Author: Min, Myintzu, primary, Spelman, Tim, additional, Lugaresi, Alessandra, additional, Boz, Cavit, additional, Spitaleri, Daniele LA, additional, Pucci, Eugenio, additional, Grand’Maison, Francois, additional, Granella, Franco, additional, Izquierdo, Guillermo, additional, Butzkueven, Helmut, additional, Sanchez-Menoyo, Jose Luis, additional, Barnett, Michael, additional, Girard, Marc, additional, Trojano, Maria, additional, Grammond, Pierre, additional, Duquette, Pierre, additional, Sola, Patrizia, additional, Alroughani, Raed, additional, Hupperts, Raymond, additional, Vucic, Steve, additional, Kalincik, Tomas, additional, Van pesch, Vincent, additional, and Lechner-Scott, Jeannette, additional
Published: 2018
Full Text: View/download PDF

45. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Author: UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Kalincik, Tomas, Brown, J William L, Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M, Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent, Rozsa, Csilla, Grand'Maison, François, Boz, Cavit, Granella, Franco, Slee, Mark, Spitaleri, Daniele, Olascoaga, Javier, Bergamaschi, Roberto, Verheul, Freek, Vucic, Steve, McCombe, Pamela, Hodgkinson, Suzanne, Sanchez-Menoyo, Jose Luis, Ampapa, Radek, Simo, Magdolna, Csepany, Tunde, Ramo, Cristina, Cristiano, Edgardo, Barnett, Michael, Butzkueven, Helmut, Coles, Alasdair, MSBase Study Group, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Kalincik, Tomas, Brown, J William L, Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M, Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent, Rozsa, Csilla, Grand'Maison, François, Boz, Cavit, Granella, Franco, Slee, Mark, Spitaleri, Daniele, Olascoaga, Javier, Bergamaschi, Roberto, Verheul, Freek, Vucic, Steve, McCombe, Pamela, Hodgkinson, Suzanne, Sanchez-Menoyo, Jose Luis, Ampapa, Radek, Simo, Magdolna, Csepany, Tunde, Ramo, Cristina, Cristiano, Edgardo, Barnett, Michael, Butzkueven, Helmut, Coles, Alasdair, and MSBase Study Group
Abstract: BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years. METHODS: In this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts. Longitudinal clinical data were obtained from 71 MSBase centres in 21 countries and from six non-MSBase centres in the UK and Germany between Nov 1, 2015, and June 30, 2016. Key inclusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one of the study therapies (alemtuzumab, interferon beta, fingolimod, or natalizumab), age 65 years or younger, Expanded Disability Status Scale (EDSS) score 6·5 or lower, and no more than 10 years since the first multiple sclerosis symptom. The primary endpoint was annualised relapse rate. The secondary endpoints were cumulative hazards of relapses, disability accumulation, and disability improvement events. We compared relapse rates with negative binomial models, and estimated cumulative hazards with conditional proportional hazards models. FINDINGS: Patients were treated between Aug 1, 1994, and June 30, 2016. The cohorts consisted of 189 patients given alemtuzumab, 2155 patients given interferon beta, 828 patients given fingolimod, and 1160 patients given natalizumab. Alemtuzumab was associated with a lower annualised relapse rate than interferon beta (0·19 [95% CI 0·14-0·23] vs 0·53 [0·46-0·61], p<0·0001) and fingolimod (0·15 [0·10-0·20] vs 0·34 [0·26-0·41], p<0·0001), and was associated with a similar annualised relapse rate as natalizumab (0·20 [0·14-0·26] vs 0·19 [0·15-0·23], p=0·78). For the disability outcome
Published: 2017

46. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Author: Signori, Alessio, primary, Izquierdo, Guillermo, additional, Lugaresi, Alessandra, additional, Hupperts, Raymond, additional, Grand’Maison, Francois, additional, Sola, Patrizia, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Boz, Cavit, additional, Grammond, Pierre, additional, Terzi, Murat, additional, Singhal, Bhim, additional, Alroughani, Raed, additional, Petersen, Thor, additional, Ramo, Cristina, additional, Oreja-Guevara, Celia, additional, Spitaleri, Daniele, additional, Shaygannejad, Vahid, additional, Butzkueven, Helmut, additional, Kalincik, Tomas, additional, Jokubaitis, Vilija, additional, Slee, Mark, additional, Fernandez Bolaños, Ricardo, additional, Sanchez-Menoyo, Jose Luis, additional, Pucci, Eugenio, additional, Granella, Franco, additional, Lechner-Scott, Jeannette, additional, Iuliano, Gerardo, additional, Hughes, Stella, additional, Bergamaschi, Roberto, additional, Taylor, Bruce, additional, Verheul, Freek, additional, Edite Rio, Maria, additional, Amato, Maria Pia, additional, Sajedi, Seyed Aidin, additional, Majdinasab, Nastaran, additional, Van Pesch, Vincent, additional, Sormani, Maria Pia, additional, and Trojano, Maria, additional
Published: 2017
Full Text: View/download PDF

47. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Author: Kalincik, Tomas, primary, Brown, J William L, additional, Robertson, Neil, additional, Willis, Mark, additional, Scolding, Neil, additional, Rice, Claire M, additional, Wilkins, Alastair, additional, Pearson, Owen, additional, Ziemssen, Tjalf, additional, Hutchinson, Michael, additional, McGuigan, Christopher, additional, Jokubaitis, Vilija, additional, Spelman, Tim, additional, Horakova, Dana, additional, Havrdova, Eva, additional, Trojano, Maria, additional, Izquierdo, Guillermo, additional, Lugaresi, Alessandra, additional, Prat, Alexandre, additional, Girard, Marc, additional, Duquette, Pierre, additional, Grammond, Pierre, additional, Alroughani, Raed, additional, Pucci, Eugenio, additional, Sola, Patrizia, additional, Hupperts, Raymond, additional, Lechner-Scott, Jeannette, additional, Terzi, Murat, additional, Van Pesch, Vincent, additional, Rozsa, Csilla, additional, Grand'Maison, François, additional, Boz, Cavit, additional, Granella, Franco, additional, Slee, Mark, additional, Spitaleri, Daniele, additional, Olascoaga, Javier, additional, Bergamaschi, Roberto, additional, Verheul, Freek, additional, Vucic, Steve, additional, McCombe, Pamela, additional, Hodgkinson, Suzanne, additional, Sanchez-Menoyo, Jose Luis, additional, Ampapa, Radek, additional, Simo, Magdolna, additional, Csepany, Tunde, additional, Ramo, Cristina, additional, Cristiano, Edgardo, additional, Barnett, Michael, additional, Butzkueven, Helmut, additional, and Coles, Alasdair, additional
Published: 2017
Full Text: View/download PDF

48. Acute disseminated encephalomyelitis: A rare autoimmune complication of herpes simplex encephalitis in the adult

Author: Bocos-Portillo, Jone, Sánchez-Menoyo, José Luis, Beldarrain, Marian Gómez, Saralegui Prieto, Ibone, Ontañón Garcés, Jose María, Dalmau, Josep, and García-Moncó, Juan Carlos
Published: 2018
Full Text: View/download PDF

49. Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia.

Author: Nieva, Aintzine Ruisanchez, Sanchez Menoyo, Jose Luis, Cortina, Ines Escalza, Beti, Nerea Foncea, Beldarrain, Marian Gomez, and Garcia-Monco, Juan Carlos
Published: 2017
Full Text: View/download PDF

50. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

Author: Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Brown, J William L, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Bergamaschi, Roberto, Sá, Maria José, Cartechini, Elisabetta, Boz, Cavit, Granella, Franco, Hupperts, Raymond, Terzi, Murat, Lechner-Scott, Jeannette, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Olascoaga, Javier, Prevost, Julie, Aguera-Morales, Eduardo, Slee, Mark, Csepany, Tunde, Turkoglu, Recai, Sidhom, Youssef, Gouider, Riadh, Van Wijmeersch, Bart, McCombe, Pamela, Macdonell, Richard, Coles, Alasdair, Malpas, Charles, Butzkueven, Helmut, Vukusic, Sandra, Kalincik, Tomas, Duquette, Pierre, Grand'Maison, Francois, Iuliano, Gerardo, Ramo-Tello, Cristina, Solaro, Claudio, Cabrera-Gomez, Jose Antonio, Rio, Maria Edite, Bolaños, Ricardo Fernandez, Shaygannejad, Vahid, Oreja-Guevara, Celia, Sanchez-Menoyo, Jose Luis, Petersen, Thor, Altintas, Ayse, Barnett, Michael, Flechter, Shlomo, Fragoso, Yara, Amato, Maria Pia, Moore, Fraser, Ampapa, Radek, Verheul, Freek, Hodgkinson, Suzanne, Cristiano, Edgardo, Yamout, Bassem, Laureys, Guy, Dominguez, Jose Andres, Zwanikken, Cees, Deri, Norma, Dobos, Eniko, Vrech, Carlos, Butler, Ernest, Rozsa, Csilla, Petkovska-Boskova, Tatjana, Karabudak, Rana, Rajda, Cecilia, Alkhaboori, Jabir, Saladino, Maria Laura, Shaw, Cameron, Shuey, Neil, Vucic, Steve, Sempere, Angel Perez, Campbell, Jamie, Piroska, Imre, Taylor, Bruce, van der Walt, Anneke, Kappos, Ludwig, Roullet, Etienne, Gray, Orla, Simo, Magdolna, Sirbu, Carmen-Adella, Brochet, Bruno, Cotton, François, De Sèze, Jérôme, Dion, Armelle, Douek, Pascal, Guillemin, Francis, Laplaud, David, Lebrun-Frenay, Christine, Moreau, Thibault, Olaiz, Javier, Pelletier, Jean, Rigaud-Bully, Claire, Stankoff, Bruno, Marignier, Romain, Debouverie, Marc, Edan, Gilles, Ciron, Jonathan, Ruet, Aurélie, Collongues, Nicolas, Lubetzki, Catherine, Vermersch, Patrick, Labauge, Pierre, Defer, Gilles, Cohen, Mikaël, Fromont, Agnès, Wiertlewsky, Sandrine, Berger, Eric, Clavelou, Pierre, Audoin, Bertrand, Giannesini, Claire, Gout, Olivier, Thouvenot, Eric, Heinzlef, Olivier, Al-Khedr, Abdullatif, Bourre, Bertrand, Casez, Olivier, Cabre, Philippe, Montcuquet, Alexis, Créange, Alain, Camdessanché, Jean-Philippe, Faure, Justine, Maurousset, Aude, Patry, Ivania, Hankiewicz, Karolina, Pottier, Corinne, Maubeuge, Nicolas, Labeyrie, Céline, Nifle, Chantal, University of Melbourne, The Royal Melbourne Hospital, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Swinburne University of Technology [Melbourne], Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, University of Cambridge [UK] (CAM), Medicine Charles University and General Faculty Hospital in Prague, University of Bari Aldo Moro (UNIBA), University of Catania [Italy], Hospital Universitario Virgen Macarena [Seville, Spain], University 'G. d'Annunzio' of Chieti-Pescara [Chieti], Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Université de Montréal (UdeM), University of Modena and Reggio Emilia, Partenaires INRAE, Dokuz Eylül Üniversitesi = Dokuz Eylül University [Izmir] (DEÜ), IRCCS Mondino Foundation, Universidade Fernando Pessoa, KTU Medical Faculty Farabi Hospital, University of Parma = Università degli studi di Parma [Parme, Italie], Zuyderland Ziekenhuis, Medical Faculty [Samsun, Turkey], University of Newcastle [Australia] (UoN), Université Catholique de Louvain = Catholic University of Louvain (UCL), Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Hospital Universitario Donostia, Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Haydarpasa Numune Training and Research Hospital, Hasselt University (UHasselt), University of Queensland [Brisbane], Hitachi Cambridge Laboratory [University of Cambridge], Hitachi, Ltd-University of Cambridge [UK] (CAM), Monash University [Melbourne], Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Ospedali Riuniti di Salerno, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), 1157717, National Health and Medical Research Council, Biogen, MSIF-ARSEP McDonald, Melbourne Research Scholarship, French State, ‘Agence Nationale de la Recherche,’, ANR-10-COHO-002, ‘Investments for the Future’, Eugène Devic EDMUS Foundation, ARSEP Foundation, Novartis, Merck, Roche, Teva Pharmaceutical Industries, Sanofi Genzyme, EDMUS Foundation, UCL - SSS/IONS/CEMO - Pôle Cellulaire et moléculaire, UCL - (SLuc) Service de neurologie, Roos I., Leray E., Frascoli F., Casey R., Brown W.J.L., Horakova D., Havrdova E.K., Trojano M., Patti F., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., Prat A., Girard M., Grammond P., Sola P., Ferraro D., Ozakbas S., Bergamaschi R., Sa M.J., Cartechini E., Boz C., Granella F., Hupperts R., Terzi M., Lechner-Scott J., Spitaleri D., van Pesch V., Soysal A., Olascoaga J., Prevost J., Aguera-Morales E., Slee M., Csepany T., Turkoglu R., Sidhom Y., Gouider R., van Wijmeersch B., McCombe P., Macdonell R., Coles A., Malpas C.B., Butzkueven H., Vukusic S., Kalincik T., Duquette P., Grand'Maison F., Iuliano G., Ramo-Tello C., Solaro C., Cabrera-Gomez J.A., Rio M.E., Bolanos R.F., Shaygannejad V., Oreja-Guevara C., Sanchez-Menoyo J.L., Petersen T., Altintas A., Barnett M., Flechter S., Fragoso Y., Amato M.P., Moore F., Ampapa R., Verheul F., Hodgkinson S., Cristiano E., Yamout B., Laureys G., Dominguez J.A., Zwanikken C., Deri N., Dobos E., Vrech C., Butler E., Rozsa C., Petkovska-Boskova T., Karabudak R., Rajda C., Alkhaboori J., Saladino M.L., Shaw C., Shuey N., Vucic S., Sempere A.P., Campbell J., Piroska I., Taylor B., van der Walt A., Kappos L., Roullet E., Gray O., Simo M., Sirbu C.-A., Brochet B., Cotton F., de Seze J., Dion A., Douek P., Guillemin F., Laplaud D., Lebrun-Frenay C., Moreau T., Olaiz J., Pelletier J., Rigaud-Bully C., Stankoff B., Marignier R., Debouverie M., Edan G., Ciron J., Ruet A., Collongues N., Lubetzki C., Vermersch P., Labauge P., Defer G., Cohen M., Fromont A., Wiertlewsky S., Berger E., Clavelou P., Audoin B., Giannesini C., Gout O., Thouvenot E., Heinzlef O., Al-Khedr A., Bourre B., Casez O., Cabre P., Montcuquet A., Creange A., Camdessanche J.-P., Faure J., Maurousset A., Patry I., Hankiewicz K., Pottier C., Maubeuge N., Labeyrie C., Nifle C., Brown, Will [0000-0002-7737-5834], Coles, Alasdair [0000-0003-4738-0760], Apollo - University of Cambridge Repository, McCombe, Pamela/0000-0003-2704-8517, Slee, Mark/0000-0003-4323-2453, Brown, William/0000-0002-7737-5834, Laplaud, David/0000-0001-6113-6938, Ciron, Jonathan/0000-0002-3386-6308, Roos, Izanne/0000-0003-0371-3666, Lugaresi, Alessandra/0000-0003-2902-5589, Aguera-Morales, Eduardo/0000-0002-8604-2054, Kalincik, Tomas, Girard, Marc, Patti, Francesco, Horakova, Dana, Malpas, Charles B., Olascoaga, Javier, Prevost, Julie, Roos, Izanne, Hupperts, Raymond, Csepany, Tunde, VAN WIJMEERSCH, Bart, Ferraro, Diana, Aguera-Morales, Eduardo, Cartechini, Elisabetta, Vukusic, Sandra, Frascoli, Federico, Lugaresi, Alessandra, Sa, Maria Jose, Butzkueven, Helmut, Spitaleri, Daniele, Macdonell, Richard, Coles, Alasdair, Havrdova, Eva K., Granella, Franco, Turkoglu, Recai, Trojano, Maria, Sola, Patrizia, Van Pesch, Vincent, Onofrj, Marco, Grammond, Pierre, Bergamaschi, Roberto, Izquierdo, Guillermo, McCombe, Pamela, Slee, Mark, Eichau, Sara, Prat, Alexandre, Leray, Emmanuelle, Soysal, Aysun, Terzi, Murat, Brown, J. William L., Boz, Cavit, Sidhom, Youssef, Gouider, Riadh, Ozakbas, Serkan, Casey, Romain, Lechner-Scott, Jeannette, Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Hospital Universitario Virgen Macarena [Séville], Università degli studi di Parma = University of Parma (UNIPR), University of Newcastle [Callaghan, Australia] (UoN), University of Cambridge [UK] (CAM)-Hitachi, Ltd, and ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010)
Subjects: Adult, Male, medicine.medical_specialty, Multiple Sclerosis, Time Factors, multiple sclerosis, law.invention, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Natalizumab, Randomized controlled trial, law, Internal medicine, medicine, Humans, Immunologic Factors, Multiple sclerosi, 030212 general & internal medicine, Prospective Studies, Registries, Prospective cohort study, therapeutic lag, business.industry, Multiple sclerosis, Interferon beta-1a, Middle Aged, medicine.disease, Fingolimod, 3. Good health, Treatment Outcome, Cohort, Disease Progression, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Neurology (clinical), business, Immunotherapies, 030217 neurology & neurosurgery, Immunosuppressive Agents, Therapeutic lag, prognosis, treatment, medicine.drug, Cohort study, Follow-Up Studies
Abstract: In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we aimed to develop a method that allows identification of the time to manifest fully and clinically the effect of multiple sclerosis treatments ('therapeutic lag') on clinical disease activity represented by relapses and progression-of-disability events. Data from two multiple sclerosis registries, MSBase (multinational) and OFSEP (French), were used. Patients diagnosed with multiple sclerosis, minimum 1-year exposure to treatment, minimum 3-year pretreatment follow-up and yearly review were included in the analysis. For analysis of disability progression, all events in the subsequent 5-year period were included. Density curves, representing incidence of relapses and 6-month confirmed progression events, were separately constructed for each sufficiently represented therapy. Monte Carlo simulations were performed to identify the first local minimum of the first derivative after treatment start; this point represented the point of stabilization of treatment effect, after the maximum treatment effect was observed. The method was developed in a discovery cohort (MSBase), and externally validated in a separate, non-overlapping cohort (OFSEP). A merged MSBase-OFSEP cohort was used for all subsequent analyses. Annualized relapse rates were compared in the time before treatment start and after the stabilization of treatment effect following commencement of each therapy. We identified 11 180 eligible treatment epochs for analysis of relapses and 4088 treatment epochs for disability progression. External validation was performed in four therapies, with no significant difference in the bootstrapped mean differences in therapeutic lag duration between registries. The duration of therapeutic lag for relapses was calculated for 10 therapies and ranged between 12 and 30 weeks. The duration of therapeutic lag for disability progression was calculated for seven therapies and ranged between 30 and 70 weeks. Significant differences in the pre- versus post-treatment annualized relapse rate were present for all therapies apart from intramuscular interferon beta-1a. In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progression in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience early on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag. This study was supported by the EDMUS Foundation, Biogen and NHMRC (1140766, 1129189, 1157717). I.R. is supported by a MSIF-ARSEP McDonald fellowship grant and a Melbourne Research Scholarship. The MSBase Foundation is a not-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva and Sanofi Genzyme. The Observatoire Francais de la Sclerose en Plaques (OFSEP) is supported by a grant provided by the French State and handled by the 'Agence Nationale de la Recherche,' within the framework of the 'Investments for the Future' program, under the reference ANR-10-COHO-002, by the Eugene Devic EDMUS Foundation against multiple sclerosis and by the ARSEP Foundation. The study was conducted separately and apart from the guidance of the sponsors. Kalincik, T (corresponding author), Univ Melbourne, Dept Med, CORe, 300 Grattan St, Melbourne, Vic 3050, Australia. tomas.kalincik@unimelb.edu.au

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

89 results on '"Sanchez-Menoyo, Jose Luis"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources